+180 XP

Earnouts, contingent consideration, and deal terms

# Earnouts, contingent consideration, and deal terms

In 2016, Bayer agreed to buy Monsanto for $128 per share in all cash, no earnout, no contingent value right, no clever bridge. Bayer simply paid the seller's number. By 2020 it had absorbed over $10 billion in Roundup litigation settlements and its market cap had fallen below what it paid for the target alone. The lesson isn't "diligence harder." It's that Bayer accepted 100% of an unknowable future risk at the moment of signing because its deal structure gave it no other place to put it. A different set of terms, an escrow tied to litigation outcomes, a reps-and-warranties framework that survived closing, a portion of consideration contingent on realized liabilities, would have left billions of dollars of that risk with the party who actually created and understood it.

This is the core discipline of deal structuring: you are not negotiating a price, you are negotiating a distribution of outcomes. Price is a single number that assumes you know the future. Structure is the machinery that decides who pays when the future disagrees with the model. The CFO who treats these as separate skills overpays on the deals that look cheap and walks away from the deals that were actually winnable.

The valuation gap is information, not stubbornness

When a buyer models a target at $180 million and the seller insists on $240 million, the amateur read is that someone is wrong. The sophisticated read is that the two parties hold different probability distributions over the same future, and the $60 million gap is a *quantification of their disagreement.*

Almost always, the disagreement clusters around a small number of forward assumptions: revenue growth after the founder leaves, retention of a concentrated customer, the outcome of a pending regulatory approval, or the realizability of a pipeline. The seller, who lives inside the business, believes the pipeline converts. The buyer, who has seen a hundred pipelines, applies a haircut. Neither can prove their case at signing.

The structural insight is this: do not pay today for a belief you cannot verify today. Instead, isolate the specific assumption driving the gap and build a contingent instrument that pays the seller *if and only if* their belief turns out to be correct. You have converted an argument about valuation into an agreement about facts, facts that time will settle.

This reframes the CFO's job. Your task is not to win the price argument. It is to (1) decompose the gap into its underlying risk drivers, (2) assign each driver to the party best positioned to bear or control it, and (3) select the instrument that enforces that assignment. Risk allocation theory is unambiguous here: a risk should be borne by whoever can most cheaply influence or absorb it. The seller controls near-term operating performance; the buyer controls post-close integration and capital. Structure should follow that logic, not the balance of negotiating egos.

The instrument toolkit and what each one actually does

Each deal term is a risk-transfer device with a distinct payoff profile. Choosing among them is the substance of structuring.

Earnouts: paying for performance you can't yet see

An earnout defers a portion of consideration and ties it to post-close metrics, revenue, EBITDA, unit volume, a product milestone. It is the natural bridge for a growth-driven valuation gap, because it lets the seller monetize their optimism only if the business delivers it.

The trap is that earnouts create misaligned incentives during the earnout period and manufacture litigation. The buyer now controls the business but the seller's payout depends on it. Every integration decision, reallocating a salesforce, changing pricing, deferring a launch to the next fiscal year, can be read by the seller as sabotage designed to suppress the earnout. This is not hypothetical; earnout disputes are among the most common sources of post-close M&A litigation, and Delaware courts have repeatedly wrestled with the implied covenant of good faith in operating the target during the measurement window.

The CFO's practical rules:

  • Prefer top-line metrics over bottom-line ones. Revenue is harder to manipulate through post-close allocations, intercompany charges, and overhead pushdowns than EBITDA is. Every layer of accounting judgment between the metric and cash is a future argument.
  • Keep the measurement period short, ideally 12 to 24 months. Long earnouts (3-5 years) drift ever further from the deal thesis as the businesses merge, making attribution impossible.
  • Specify the operating covenants in writing. Define whether the buyer must run the business consistent with past practice, fund it at a minimum level, and refrain from decisions that impair the metric. Vagueness here is where lawsuits are born.
  • Model the earnout as an option, not a discount. Contingent consideration must be recorded at fair value at acquisition date and remeasured each period through the income statement (under ASC 805 / IFRS 3). A growing target means a growing liability and a P&L charge, precisely when the business is winning. Explain this dynamic to your board *before* closing, or you will be explaining a "surprise" earnings hit later.

Escrows and holdbacks: reserving cash against known unknowns

Where an earnout funds seller upside, an escrow protects buyer downside. A portion of purchase price, commonly 10-15%, is held by a third party for 12-24 months to satisfy claims for breached representations, undisclosed liabilities, or working-capital adjustments. The escrow is a pre-funded recourse mechanism: it converts the buyer's post-close claim from a lawsuit into a simple release-of-funds negotiation. The party holding the cash holds the leverage.

The distinction to internalize: an escrow addresses risks that *already exist but are not yet measured* (a tax exposure, a customer that may churn). An earnout addresses value that *does not yet exist and may never*. Confusing the two produces structures that protect the wrong party against the wrong risk.

Reps, warranties, and indemnification: the allocation of the unknown

Representations are the seller's factual assertions about the business; warranties promise those facts are true; indemnification is the remedy when they aren't. Together they form the contractual risk allocation grid, governed by three levers the CFO must negotiate deliberately:

  • Survival period, how long after closing a rep can be claimed against. Fundamental reps (title, authority, taxes) survive long; general operating reps often survive only 12-18 months.
  • Caps, the maximum indemnifiable amount, frequently sized to the escrow for general reps but reaching full purchase price for fraud and fundamental reps.
  • Baskets and deductibles, thresholds below which no claim is paid, filtering out nuisance-level noise so the mechanism only fires on material breaches.

Reps, Warranties, and Indemnification Explained

Watch on YouTube

Representations & warranties insurance: outsourcing the allocation

Over the last decade, R&W insurance has moved from exotic to default in the middle market. For a premium of roughly 2-4% of coverage, an insurer assumes the indemnification obligation, allowing a clean exit for sellers (no large escrow, no lingering claw-back) while giving buyers a solvent, deep-pocketed counterparty instead of chasing a dispersed selling group. For the CFO, R&W insurance is a tool to *unlock a deal where the seller demands liquidity* and to convert an uncertain, relationship-damaging clawback into a priced, transferable cost. The judgment call: the insurer will exclude known issues and matters surfaced in diligence, so it never substitutes for structure on the risks you actually identified, only on the unknown-unknowns.

Assembling the structure: a worked bridge

Return to the $180M-versus-$240M gap. Decompose it and the disagreement resolves into three drivers:

1. $40M hinges on whether the target's two largest customers renew (seller confident, buyer skeptical).

2. $15M reflects a pending IP dispute the seller insists is frivolous.

3. $5M is genuine negotiating spread.

A structured bridge might look like this. Pay $185M at closing, above the buyer's base case, splitting the pure spread. Place $40M into a two-year revenue earnout conditioned on retention of the named accounts, with explicit covenants requiring the buyer to maintain existing service levels and pricing. Hold $15M in escrow released only upon resolution of the IP matter, with any adverse judgment funded first from escrow. Layer R&W insurance across the general reps so the seller walks with clean proceeds on everything else.

The seller can now reach $240M, but only by proving the business is worth it. The buyer caps its true exposure at $185M plus outcomes it verified were real. Neither party paid for a belief. The gap didn't close; it got *distributed to the parties who each thought they were right,* and time will pay whoever was.

Knowledge check

1. According to the lesson, what is the fundamental mistake a CFO makes when treating price and structure as separate skills?

2. The lesson argues that deal structuring is fundamentally about which of the following?

3. In the lesson's framing, what does a large valuation gap between buyer and seller most accurately represent?

MULTIPLE CHOICE

4. Select ALL statements that correctly reflect the lesson's structural insight about contingent instruments and valuation gaps.

Select all the correct answers.

MULTIPLE CHOICE

5. Select ALL of the structural mechanisms the lesson identifies as ways Bayer could have shifted future risk back to the party who understood it best.

Select all the correct answers.

The second-order costs structure imposes

Structure is not free, and the CFO who reaches for it reflexively creates a different set of problems.

Complexity is a liability. Every contingent term is a future measurement obligation, a potential dispute, and a line item your controllers must track for years. A three-tranche earnout with quarterly EBITDA measurement and adjustment clauses is a full-time job for someone in your organization. The accounting alone, fair-valuing and remeasuring contingent consideration under ASC 805 each reporting period, with the changes hitting earnings, can inject volatility into your P&L that analysts will question and that has nothing to do with operating performance.

Structure signals distrust. In competitive auctions, a seller with multiple bidders will discount a heavily contingent offer relative to clean cash, even at a higher headline number, because certainty has value. A private-equity buyer offering $200M all-cash will often beat a strategic offering $230M with half in earnout. The CFO must price the *certainty premium* the market demands and recognize that in a hot process, elegant structure loses to simple cash.

Earnouts govern the integration you actually want. The most under-appreciated cost is strategic. An earnout tied to the target's standalone revenue can *forbid you from doing the integration that justified the deal*, cross-selling, consolidating salesforces, killing overlapping products, because each move risks depressing the standalone metric and triggering a dispute. You bought the company to combine it and then signed a contract that penalizes combination. Resolve this tension at the negotiating table, not in year two.

The discipline, then, is to reach for structure precisely where the valuation gap is (a) large, (b) concentrated in one or two verifiable drivers, and (c) resolvable within a short, measurable window. Where the gap is diffuse, where the metric is manipulable, or where integration must move fast, take the pain in the price and buy the business clean.

Key Takeaways

  • Decompose every valuation gap into its risk drivers before negotiating structure. The gap is not stubbornness, it is a quantified disagreement about specific forward assumptions. Isolate them, and each becomes an addressable contingent instrument rather than a stalemate.
  • Match the instrument to the risk profile: earnouts for unrealized upside, escrows for measured-but-unresolved liabilities, reps and warranties for the unknown, R&W insurance for a clean exit. Using the wrong tool protects the wrong party against the wrong risk.
  • Build earnouts on top-line metrics, keep the window under 24 months, and write the operating covenants explicitly. EBITDA-based, long-dated, vaguely governed earnouts are litigation factories that also constrain the integration you did the deal to achieve.
  • Model contingent consideration through the P&L before you sign, not after. ASC 805 remeasurement means a winning target grows an earnings-charging liability, brief your board on this dynamic in advance or own the surprise later.
  • Price the certainty premium. Structure signals distrust and adds years of administrative cost; in a competitive process, clean cash frequently beats a higher contingent number. Reach for structure only when the gap is large, concentrated, and resolvable in a short window.

What to do, from this lesson

These actions are compiled in the role's Playbook.

  • Match pricing mechanism and instrument to the asset's risk profile
  • Build earnouts on top-line metrics under 24 months with explicit covenants
See the full action playbook